Clare Pelham comments on new sodium valproate regulations
Our chief executive Clare Pelham, a member of the Commission on Human Medicines' Sodium Valproate Expert Working Group, commented on the news of the new regulations surrounding sodium valproate.
Charity tells health secretary new drug regulations could fail without public campaign
Epilepsy Society today welcomes new regulatory measures to stop babies being born with avoidable disabilities after being exposed to the drug, sodium valproate, in the womb.
Poster campaign raises awareness of epilepsy on public transport
This week, for the first time ever, epilepsy is featuring as part of a high profile poster campaign across London's underground and bus networks.
Epilepsy Society welcomes new measures to ensure no babies are exposed to sodium valproate during pregnancy
New measures announced to stop babies being exposed to valproate in the womb
Valproate medicines are available in the UK under brand names such as Epilim, Epival, Episenta, Convulex and Orlept
No girl or woman should stop taking valproate without first consulting her doctor.
Epilepsy Society praises Government decision to review handling of concerns around sodium valproate
Epilepsy Society's chief executive Clare Pelham has praised the Government's decision to announce a forward-looking review that will address the way the healthcare system has handled the concerns of patients in its care and make certain that lessons are learned and history does not repeat itself.
EMA publishes recommendations on sodium valproate
New measures to avoid the exposure of unborn babies to the epilepsy drug sodium valproate have been announced by the safety committee of the European Medicines Agency (EMA).